制备技术如Aphios 公司的超临界流体技术和Polymun 的交叉流注射技术，或是独特的脂质体类型 如ALZA 公司的STEALTH.脂质体、Skyepharma 公司的Depofoam.。正是这些专利技术保证了这些脂质体公司的竞争力和生命力。


参考文献：
[1] Abra RM, Bankert RB, Chen F, et al. The next generation of liposome delivery systems: recent experience with

第3 期 李春雷等：国外部分公司脂质体药物研发现状 77
tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients [J]. J Liposome Res, 2002, 12
(1-2): 1-3.
[2] Working PK, Newman MS, Sullivan T, et al. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs
byencapsulation in long-circulating, pegylated liposomes [J]. J Pharmacol Exp Ther, 1999, 289 (2): 1128-1133.
[3] Perez-Soler R, Khokhar AR. Delivery and activation through liposome incorporation of diaminocyclohexane
platinum (II) complexes [P]. US: 5843475, 1998-12-01.
[4] Mehta K, Perez-Soler R, Lopez-Berestein G, et al. Formulation and use of carotenoids in treatment of cancer [P]. US:
6200597, 2001-03-13.
[5] Castor TP. Methods and apparatus for making liposomes [P]. US: 5554382, 1996-09-10.
[6] Castor TP, Chu L. Methods and apparatus for making liposomes containing hydrophobic drugs [P]. US: 5776486,
1998-07-07.
[7] Moser C, Metcalfe IC, Viret JF. Virosomal adjuvanted antigen delivery systems [J]. Expert Rev Vaccines, 2003, 2(2):
189-196.
[8] Jiang ZH, Koganty RR. Synthetic vaccines: the role of adjuvants in immune targeting [J]. Curr Med Chem, 2003,
10(15): 1423-1439.
[9] Batenjany MM, Boni LT, Guo Y, et al. The effect of cholesterol in a liposomal Muc1 vaccine. Biochim Biophys Acta,
2001, 1514(2): 280-290.
[10] Needham D. Temperature-sensitive liposomal formulation [P]. US: 6200598, 2001-03-13.
[11] Swenson CE, Bolcsak LE, Batist G, et al. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99;
liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination
with cyclophosphamide in patients with metastatic breast cancer [J]. Anticancer Drugs, 2003, 14(3): 239-246.
[12] Forssen EA, Male-Brune R, Adler-Moore JP, et al. Fluorescence imaging studies for the disposition of daunorubicin
liposomes (DaunoXome) within tumor tissue [J]. Cancer Res, 1996, 56(9): 2066-2075.
[13] Adler-Moore J. AmBisome targeting to fungal infections [J]. Bone Marrow Transplant, 1994, 14 (S5): 3-7.
[14] Cullis PR, Chonn A. Recent advances in liposome technologies and their applications for systemic gene delivery [J].
Adv Drug Deliv Rev, 1998, 30(1-3): 73-83.
[15] Bacon A, Caparros-Wanderley W, Zadi B, et al. Induction of a cytotoxic T lymphocyte (CTL) response to plasmid
DNA delivered via Lipodine liposomes [J]. J Liposome Res, 2002, 12(1-2): 173-183.
[16] Zhang JA, Xuan T, Parmar M, et al. Development and characterization of a novel liposome-based formulation of
SN-38 [J]. Int J Pharm, 2004, 270(1-2): 93-107.
[17] Guo W, Ahmad A, Khan S, et al. Determination by liquid chromatography with fluorescence detection of
total7-ethyl-10-hydroxy-camptothecin (SN-38) in beagle dog plasma after intravenous administration of
liposome-based SN-38 (LE-SN38) [J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2003, 791(1-2): 85-92.
[18] Wagner A, Vorauer-Uhl K, Katinger H. Liposomes produced in a pilot scale: production, purification and efficiency
aspects [J]. Eur J Pharm Biopharm, 2002, 54(2): 213-219.

78 中 国 药 剂 学 杂 志 第2 卷
[19] Langston MV, Ramprasad MP, Kararli TT, et al. Modulation of the sustained delivery of myelopoietin (Leridistim)
encapsulated in multivesicular liposomes (DepoFoam) [J]. J Control Release, 2003, 89(1): 87-99.
[20] Mantripragada S. A lipid based depot (DepoFoam technology) for sustained release drug delivery [J]. Prog Lipid
Res, 2002, 41(5): 392-406.
[21] Perez-Soler R, Pilkiewicz F. Method for treating lung cancers [P]. WO: 03015707, 2003-02-27.
Current status of liposomal drugs developed by partial foreign
companies
LI Chun-lei, DENG Ying-jie
(School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016,China)
Abstract: Object To review the development status of liposomal drugs in foreign companies. Method
Based on information from published literatures and from internet web, the liposome technologies and
liposomal drugs developed by 14 biopharmaceutical companies were introduced. Result and
Conclusion It can be concluded that three kinds of liposomal drugs have been studied intensively,